<?xml version="1.0" encoding="UTF-8"?>
<div class="fig" id="PMC7033156/figure_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption> Use of antiviral prophylaxis for anti-HBc-positive patients receiving treatments for haematological conditions. Prescription of antiviral prophylaxis to avoid HBV reactivation differed according to the underlying malignancy and therapy scheme. Screening was clearly higher in patients treated with anti-CD20-containing regimens and those with follicular lymphoma, and was lower in TKI-treated patients. DLBCL, Diffuse B cell lymphoma; CLL/CML, chronic lymphocytic/myeloid leukaemia; CR, containing regimen; TKI, tyrosine-kinase inhibitors. </caption>
 <div class="graphic"/>
 <p class="label">Figure 3</p>
</div>
